



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

August 14, 2013

NATCO turns out better performance

Hyderabad based **NATCO** Pharma Limited has clocked an aggregate of Rs.182 Crores in consolidated Revenues for the quarter ended on 30th June, 2013, as against Rs. 151 Crores during the same quarter last year, recording an increase of around 21%. The net profit, after tax, on a consolidated basis, improved to Rs.2178 lakhs, as against Rs. 1707 lakhs same quarter last year. This amounts to an increase of around 28%.

On a stand-alone basis, the revenues improved by 23% (Rs. 154 Crores as against Rs. 125 Crores), while the net profit after tax, improved by 25% (Rs. 2274 lakhs as against 1818 lakhs).

API exports and finished dosage pharmaceutical formulations exports continue to drive the growth.

With a favorable verdict having been received from the Federal Circuit Court, the Company is awaiting US FDA approval of its ANDA for Glatiramer Acetate (Copaxone®) for a possible launch in May 2014 in association with Mylan Inc.

Forwarded for favor of publication

For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M Adinarayana".

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)